Live Breaking News & Updates on Heyman Fellow At Harvard Law School

This Viewpoint discusses the controversy surrounding the FDA’s efforts to withdraw Makena from the market and the broader implications for the accelerated appro ....

Danielg Aaron , Covis Pharma , Centers For Disease , Centers For Medicare Medicaid Services , Heyman Fellow At Harvard Law School , Drug Administration , Disease Control , Medicaid Services , Heyman Fellow , Harvard Law School , Interest Disclosures ,